GLAXO \u2014 Recent Activity

GlaxoSmithKline Pharmaceuticals Ltd (BOM:500660) Q2 2026 Earnings Call Highlights: Navigating ...

Despite a sales decline, GlaxoSmithKline Pharmaceuticals Ltd (BOM:500660) showcases resilience with improved margins and robust specialty business growth.

Click to open →

GSK Licenses Shigella Vaccine to Bharat Biotech

GSK plc (NYSE:GSK) is one of the 12 best healthcare stocks to buy now. On June 12, the company announced licensing its Shigella vaccine candidate to Bharat Biotech. The licensing is part of the company’s effort to get the vaccine to patients where the pathogen poses a significant threat of causing death from diarrhea. Shigella […]

Click to open →

Patents and economies of scale support Pfizer's wide moat

Patent-protected drugs provide strong pricing power, enabling returns on invested capital.

Click to open →

Myriad (MYGN) Up 23.9% Since Last Earnings Report: Can It Continue?

Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Click to open →

Glaxo (GSK) Up 3.2% Since Last Earnings Report: Can It Continue?

Glaxo (GSK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Click to open →

Is GSK PLC Sponsored ADR (GSK) Outperforming Other Medical Stocks This Year?

Here is how GSK (GSK) and Amarin (AMRN) have performed compared to their sector so far this year.

Click to open →

GSK plc (GSK) Stock Rises as FDA Approves Nucala for COPD, CHMP Backs Blenrep for Cancer Treatment

GSK plc (NYSE:GSK) has strengthened its market outlook following major regulatory milestones. The U.S. FDA’s recent approval of Nucala for chronic obstructive pulmonary disease (COPD) and a positive recommendation from the Committee for Medicinal Products for Human Use (CHMP) for Blenrep in multiple myeloma signal significant expansion in GSK’s high-demand therapeutic portfolio. These advances are […]

Click to open →

GSK plc (GSK)’s Asthma Drug Gets FDA Nod to Treat ‘Smoker’s Lung’

The U.S. Food and Drug Administration has approved GSK plc (NYSE:GSK)’s asthma medication, Nucala, for expanded use in treating a form of chronic obstructive pulmonary disease (COPD), often referred to as “smoker’s lung,” the company announced Thursday. This decision allows Nucala to be used as an add-on therapy for patients with a specific type of […]

Click to open →

ATS 2025: GSK strengthens argument for twice-annual depemokimab

Depemokimab reduces exacerbations regardless of baseline asthma control, suggesting uncontrolled symptoms are not necessary for response.

Click to open →

Why These 4 Women-Run Companies Deserve a Spot in Your Portfolio?

Invest in women-led companies shaping the future of business

Click to open →